Abstract
Immunoproteasome is an emerging biological target that constitutes a key element not only in antigen presentation but also in T cell and cytokine regulation as well as cellular homeostasis. Respect to standard proteasome, the inducible expression and different sensitivity towards activity modulators of immunoproteasome render it a potential therapeutic target for tumours and central nervous system diseases. In this review we report the cutting edge studies for understanding when immunoproteasome expression is induced and how it regulates pivotal pathways involved in tumours and neuropathologies, including apoptosis and inflammation. We emphasize its role as a new pharmacological target by describing the recent medicinal chemistry efforts aimed at design selective small-molecule modulators of both standard- and immuno-proteasome forms. Finally, we also present an in silico model of the human immunoproteasome structure by the major molecular differences with the 20S standard proteasome and discuss the perspective for the design of novel specific smallmolecule modulators for the different proteasome isoforms.
Current Pharmaceutical Design
Title:Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Volume: 19 Issue: 4
Author(s): Elena Bellavista, Federico Andreoli, Marco Daniele Parenti, Morena Martucci, Aurelia Santoro, Stefano Salvioli, Miriam Capri, Agostino Baruzzi, Alberto Del Rio, Claudio Franceschi, Michele Mishto
Affiliation:
Abstract: Immunoproteasome is an emerging biological target that constitutes a key element not only in antigen presentation but also in T cell and cytokine regulation as well as cellular homeostasis. Respect to standard proteasome, the inducible expression and different sensitivity towards activity modulators of immunoproteasome render it a potential therapeutic target for tumours and central nervous system diseases. In this review we report the cutting edge studies for understanding when immunoproteasome expression is induced and how it regulates pivotal pathways involved in tumours and neuropathologies, including apoptosis and inflammation. We emphasize its role as a new pharmacological target by describing the recent medicinal chemistry efforts aimed at design selective small-molecule modulators of both standard- and immuno-proteasome forms. Finally, we also present an in silico model of the human immunoproteasome structure by the major molecular differences with the 20S standard proteasome and discuss the perspective for the design of novel specific smallmolecule modulators for the different proteasome isoforms.
Export Options
About this article
Cite this article as:
Stefano Salvioli, Miriam Capri, Agostino Baruzzi, Alberto Del Rio, Claudio Franceschi, Michele Mishto Elena Bellavista, Federico Andreoli, Marco Daniele Parenti, Morena Martucci, Aurelia Santoro,, Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?, Current Pharmaceutical Design 2013; 19 (4) . https://dx.doi.org/10.2174/1381612811306040702
DOI https://dx.doi.org/10.2174/1381612811306040702 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteasome Regulators: Activators and Inhibitors
Current Medicinal Chemistry Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design Bergamot Juice Extract Inhibits Proliferation by Inducing Apoptosis in Human Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets Cytotoxic Molecules from Natural Sources: Tapping the Brazilian Biodiversity
Anti-Cancer Agents in Medicinal Chemistry Radiolabeled Nucleoside Analogues for PET Imaging of HSV1-tk Gene Expression
Current Topics in Medicinal Chemistry Preparation, Characterization and <i>In Vitro</i> Biological Evaluation of Novel Curcumin Derivatives as Cytotoxic and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Modulation of Genome and Proteome Alterations in Mice Treated with the Endocrine Disruptor Bisphenol A
Current Cancer Drug Targets Evaluation of the Soluble Pectin Content in Culinary Preparations
Current Nutrition & Food Science Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry Editorial (Thematic Issue: Measurements of ABC Transporters at the Blood-Brain Barrier: Novel Methods and Applications)
Current Pharmaceutical Design Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design Serotonin (5-HT) Drugs: Effects on Appetite Expression and Use for the Treatment of Obesity
Current Drug Targets Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain
Current Pharmaceutical Design Determination of Isoflavones in Legumes by QuEChERS-Capillary Electrophoresis-Electrospray Ionization-Mass Spectrometry
Current Analytical Chemistry Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Current Protein & Peptide Science Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression
Current Protein & Peptide Science Research and Development of Nuclear Molecular Imaging in Taiwan
Current Medical Imaging